The abstract is read at the publisher; the summary is JClub's.
Disease-modifying therapies for type 1 diabetes have reduced progressive β-cell function loss, but only one has regulatory approval and few phase 3 trials exist.
- Why it matters: The field needs faster, more efficient development of new and repurposed treatments, and regulatory strategy plus trial design choices are critical to achieve this.
- What they did: The article outlines a feasible road map for developers, focusing on how to plan overall regulatory strategy and clinical trial design, especially inclusion criteria and endpoint selection.
- The result: The proposed considerations support continued investment by guiding developers toward bringing emerging therapies to people living with type 1 diabetes more quickly and efficiently.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.